Introduction
ATP-sensitive K + (K ATP ) channels exist in many excitable cells, including cardiac myocytes, pancreatic b cells, muscle cells, and neurons 1, 2 and are involved in several physiological functions. 3, 4 KATP channels are expressed pre-and post-synaptically in many brain regions. They open and close in response to changes in intracellular ATP/ADP ratios. Low ATP levels open these channels, allowing K + efflux and cell hyperpolarization. 5 Therefore, the activity of K ATP channels is regulated by cell metabolism and provides a means of linking the electrical activity of a cell to its metabolic state. 6 Pharmacological studies have also demonstrated that K ATP channels play an important role in the control of seizure threshold in several in vitro and in vivo models. 3, [7] [8] [9] [10] [11] [12] Moreover, it has been shown that mice lacking a subunit of K ATP channels (Kir 6.2 À/À mice) are vulnerable to hypoxia, exhibiting a reduced threshold for generalized seizure. 9 Transgenic mice, overexpressing the sulfonylurea receptor (SUR1) gene in the forebrain, show a significant increase in the threshold for kainite-induced seizures. 13 Thus, physiopathologic conditions altering the K ATP activation could possibly affect the seizure threshold. Diabetes mellitus affects over 350 million people worldwide and 20 million people in the United States and the number of people with diabetes is increasing by 5% per year. 14 This condition has profound effect on both central and peripheral nervous system and disrupts normal cellular metabolism in many complicationprone cell types and is especially damaging to neurons.
Although there is evidence that diabetes affects seizure susceptibility, the underlying mechanism has not been completely understood. Several studies also suggest a pivotal role for K ATP channels in the seizure modulation. The aim of the present study was to evaluate the seizure threshold induced by pentylenetetrazole in diabetic mice at different times (3 days, 1-8 weeks) after induction of diabetes with streptozocin and to examine the possible role of ATP-sensitive potassium (K ATP ) channels in this manner.
Our data showed a time-dependent alteration in the threshold in diabetic mice, reaching a peak on week 2 after streptozocin injection and declining significantly afterwards. The seizure threshold in 8-week diabetic mice was even lower than control levels, though the difference was not significant. The K ATP channel opener cromakalim (0.1-30 mg/kg, i.p.) significantly increased the seizure threshold in control mice. Although the K ATP channel blocker glibenclamide (0.5, 1 mg/kg) had no effect, it prevented the effects of the potent dose of cromakalim (30 mg/kg) on seizure threshold in control mice.
Glibenclamide (1 mg/kg, i.p.) also decreased the seizure threshold in 2-week diabetic mice to the control levels which was blocked by pre-treatment with cromakalim (10 mg/kg, i.p.). Cromakalim (10 mg/kg, i.p.) significantly increased the seizure threshold in 8-week diabetic mice which was inhibited by pretreatment with glibenclamide (1 mg/kg, i.p.).
We demonstrated a time-dependent alteration in the pentylenetetrazole-induced seizure threshold in diabetic mice. This phenomenon might be due to the probable alteration in the K ATP channel functioning during the diabetic condition.
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Several line of evidence also has shown that in the adult diabetic patients hyperglycemia can precipitate seizures. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Some studies also reported consistent results by using animal models of seizure. In this regard, it was shown that alloxan-induced diabetic hyperglycemia was associated with proconvulsant effects in the electroshock seizure model in the adult rats 29 and mice. 30 Tutka et al. also reported that bicuculline-induced seizure threshold is significantly decreased in streptozocin-induced diabetic mice. 30 Although there is some evidence that hyperglycemia mainly contributes to the alteration in the seizure threshold in diabetic animals and patients, 27, 31, 32 the underlying mechanism in this phenomenon is as yet elusive.
In view the fact that K ATP channels play a pivotal role in the seizure threshold modulation, it would be reasonable if one expected that K ATP channels might be involved in the diabetesinduced alteration in the seizure threshold. This assumption is in agreement with the large amount of studies that have shown that K ATP channels functioning are affected by long-term diabetic condition. [33] [34] [35] [36] [37] For instance, it has been reported that relaxant responses of basilar arteries to K ATP channel openers is decreased in the 12-week streptozocin (STZ)-induced diabetic rats. 38, 39 However, some studies have shown that the responses to K ATP channel activation were not altered or even increased in diabetic vascular smooth muscle in the early experimental diabetic state. [40] [41] [42] [43] According to the previous reports, it seems that the duration of experimental diabetes could be an important factor contributing to the observed effects of diabetes on the K ATP channel functioning. In this regard, we have recently demonstrated that there is a time-dependent alteration in relaxant responses to the K ATP channel opener cromakalim in corpus cavernosum tissue from STZ-induced diabetic rats. 44 However, up to now it has not been investigated the effect of duration of diabetes on the seizure threshold and the role of K ATP channels in this effect has not been shown as yet. Therefore, the aim of the present study was to investigate the effect of diabetic condition induced by STZ on the seizure threshold in mice at different times after STZ injection and to evaluate the role of K ATP channels by using the specific K ATP channel blocker glibenclamide and the selective K ATP channel opener cromakalim in this manner. The seizure paradigm that we used was the assessment of the clonic seizure threshold induced by i.v. administration of the GABA receptor antagonist pentylenetetrazole (PTZ). This paradigm represents an animal model of seizures and is very sensitive to changes in seizure susceptibility. 45, 46 2. Materials and methods
Chemicals
Drugs used were as follows: streptozocin (STZ; Sigma, St. Louis, MO, USA), cromakalim, glibenclamide and pentylenetetrazole (Sigma, Bristol, UK). Glibenclamide was dissolved in DMSO. Cromakalim was dissolved in saline. STZ was dissolved in 5 mM citrate buffer (pH 4.0). All injections were administered at a volume of 5 ml/kg. Appropriate vehicle controls were performed for each experiment.
STZ, cromakalim, glibenclamide were administered intraperitoneally (i.p.). To assess clonic seizure experiments, PTZ was administered intravenously (0.5%, i.v.). The doses were chosen based on previously published studies 7, 8 and pilot experiments.
Experimental animals
Male NMRI mice weighing 20-25 g (Pasteur Institute) were used throughout this study. Animals were housed in groups of 4-5 and were allowed free access to food and water except for the short time that animals were removed from their cages for testing. All behavioral experiments were conducted during the period between 10:00 and 13:00 with normal room light (12 h regular light/dark cycle) and temperature (22 AE 1 8C). All procedures were carried out in accordance with the institutional guidelines for animal care and use.
Animals were made insulin-dependent diabetic (type I) by intraperitoneal injection of 140 mg/kg STZ 47 ; which was dissolved in 5 mM citrate buffer (pH 4.0). Control animals only received citrate buffer. After 24 h following STZ administration, blood samples were taken from tail vein and hyperglycemia was confirmed by measuring blood glucose levels, using a glucometer (GlucoMen Glycó , A. Menarini Industrie Farmacutiche Riunite S.R.L., Italy). Animals showing fasting blood glucose higher than 250 mg/dl were considered as diabetic mice. Both vehicle-treated and STZ-induced diabetic animals were randomly divided up into seven groups of 0-, 3-day and 1-, 2-, 4-, 6-and 8-week experimental groups. Each group consisted of 8-10 animals. Subsequent analysis of serum was performed at the time of seizure threshold determination in each group.
Determination of clonic seizure threshold
PTZ-induced clonic seizure threshold was determined by inserting a 30-gauge butterfly needle into the tail vein of mice and the infusion of PTZ (0.5%) at a constant rate of 1 ml/min to unrestrained freely moving animals. Infusion was halted when forelimb clonus followed by full clonus of the body was observed. Minimal dose of PTZ (mg/kg of mice weight) needed to induce clonic seizure was considered as an index of seizure threshold. As such, seizure threshold is dependent on PTZ dose administered and time-related. 
Statistical analysis
Data are expressed as mean AE SEM of clonic seizure threshold in each experimental group. The one-way or two-way analysis of variance (ANOVA) followed by Newman-Keuls post hoc test was used to analyze the data. P < 0.05 was considered the significance level between the groups. Table 1 shows the values of blood glucose and body weight of age-matched control and diabetic mice at different times after induction of diabetes by STZ. Compared with non-diabetic mice, diabetic animals had a significant increase in their blood glucose 3 days after STZ injection (143 AE 4.5 mg/dl vs 365.8 AE 70 mg/dl; P < 0.001) which was persistent afterwards. Also, 2 weeks after induction of diabetes, diabetic animals (23.5 AE 0.88 g) significantly had less body weight in comparison with 2-week (31.3 AE 0.01 g; P < 0.05) control animals and this difference was persistent afterwards.
Results
3.1. Clonic seizure threshold (CST) in control and diabetic mice Fig. 1 shows the PTZ-induced CST in either non-diabetic or diabetic mice at different times after injection of vehicle (citrate buffer) or STZ, respectively. There was no significant difference between the CST induced by PTZ in non-diabetic mice at different times after vehicle (buffer) injection (F 6,45 = 0.1849; P > 0.05). However, the PTZ-induced CST was interestingly increased in the 3-day, 1-and 2-week diabetic groups compared with corresponding age-matched control mice (F 7,51 = 13.46; P < 0.0001; Fig. 1 ). The highest level of CST was observed 2 weeks after induction of diabetes compared to 2-week control group (53.175 AE 4.117 mg/kg vs 28.5 AE 1.670 mg/kg; P < 0.001). Moreover the PTZ-induced CST was significantly (P < 0.001) decreased in 4-and 6-week diabetic mice compared with 2-week diabetic groups and the CST in these groups was similar to 4-and 6-week control animals, respectively. The PTZ-induced CST in 8-week diabetic group (25 AE 2.10 mg/kg) was lower than 8-week control mice (31 AE 2.21 mg/kg) but the difference was not significant (P > 0.05; Fig. 1 ). 
Effect of cromakalim and glibenclamide on CST in non-diabetic control mice
glucose (mg/dl) and body weight (g) of separate groups of control and diabetic mice 0 and 3 days, 1, 2, 4, 6 and 8 weeks after injection of either citrate buffer (control) or streptozocine
Effect of glibenclamide and cromakalim on CST in 2-week diabetic mice
In this step we examined the role of glibenclamide in the elevated CST in 2-week diabetic animals. Glibenclamide or its vehicle (DMSO) was injected 30 min before PTZ. As shown in Fig. 3 , glibenclamide at 1 mg/kg (i.p.) had no significant effect on the PTZinduced CST in 2-week control animals. However, it significantly (P < 0.001) decreased the PTZ-induced CST in 2-week diabetic animals compared with vehicle-injected diabetic ones. The PTZinduced CST was similar between glibenclamide-injected 2-week diabetic animals and 2-week non-diabetic controls. Glibenclamide (1 mg/kg, i.p.) or its vehicle had no significant effect on the blood glucose in either control or diabetic mice (data not shown).
The decreasing effect of glibenclamide (1 mg/kg, i.p.) on the CST in 2-week diabetic mice was prevented by pre-treatment with the ATP-sensitive K + channel opener cromakalim (10 mg/kg, i.p.).
Cromakalim was injected into the mice 5 min before glibenclamide injection and 35 min before PTZ. Moreover, cromakalim at the same dose, alone or in combination with glibenclamide (1 mg/kg, i.p.), had no significant effect on the CST in non-diabetic control mice (Fig. 3) . Cromakalim (10 mg/kg, i.p.) or its vehicle alone or in combination with glibenclamide had no significant effect on the blood glucose in either control or diabetic mice (data not shown).
Effect of glibenclamide and cromakalim on CST in 8-week diabetic mice
In this step we first examined the effect of cromakalim on the CST in 8-week diabetic animals. Cromakalim or its vehicle (saline) was injected 30 min before PTZ. As shown in Fig. 4 , cromakalim at 10 mg/kg (i.p.) had no significant effect on the PTZ-induced CST in 8-week control animals. However, it significantly (P < 0.05) increased the PTZ-induced CST in 8-week diabetic animals compared with vehicle-injected diabetic ones. The PTZ-induced CST was similar between cromakalim-injected 8-week diabetic animals and 8-week non-diabetic controls. Cromakalim (10 mg/kg, i.p.) or its vehicle had no significant effect on the blood glucose in either control or diabetic mice (data not shown).
As shown in Fig. 4 , the increasing effect of cromakalim (10 mg/ kg, i.p.) on the CST in 8-week diabetic mice was prevented by pretreatment with glibenclamide (1 mg/kg, i.p.). Glibenclamide was injected into the mice 5 min before cromakalim injection and 35 min before PTZ. Moreover, glibencalmide at the same dose, alone or in combination with cromakalim (10 mg/kg, i.p.), had no significant effect on the CST in 8-week non-diabetic controls. Glibenclamide (1 mg/kg, i.p.) or its vehicle alone or in combination with cromakalim (10 mg/kg, i.p.) had no significant effect on the blood glucose in either 8-week control or diabetic mice (data not shown).
Discussion
In the present study, we found that in the STZ-induced diabetic mice, the threshold of PTZ-induced clonic seizures is increased in a time-dependent manner and this elevation reaches a peak on the second week after induction of diabetes with STZ injection. We also demonstrated that the PTZ-induced seizure threshold was significantly decreased in 4-, 6-and 8-week diabetic mice in a time-dependent manner compared with 2-week diabetic animals. The seizure threshold in 8-week diabetic mice was even lower than the 8-week non-diabetic control mice, though the difference was not significant. Our data also revealed that the non-effective dose of K ATP channel blocker glibenclamide prevented the increased seizure threshold in 2-week diabetic mice and this effect of glibenclamide was blocked by pre-treatment with the selective K ATP channel opener cromakalim. Additionally, cromakalim significantly increased the seizure threshold in 8-week diabetic mice but not age-matched non-diabetic mice and this effect of cromakalim was inhibited with pre-treatment with glibenclamide. These data for the first time demonstrate that K ATP channels are involved in the time-dependent alteration in the PTZ-induced seizure threshold in diabetic mice.
It is well known that K ATP channels play a pivotal role in the modulation of seizure threshold. 49 Cromakalim has been shown to reduce excitability in CA3 hippocampal cells 50 and to display antiepileptic properties in a model of drug-induced epilepsia. 10, 51 Mice with deficiencies in expression of either the SUR1 gene or the Kir6.1 gene are vulnerable to kainic acid-induced seizures, an animal model of human temporal lobe epilepsy. 52 Soundarapandian et al. have also demonstrated that expression of functional Kir6.1/SUR1 channels can be considered as an endogenous cellular Each point represents the mean AE SEM of 10 mice. **P < 0.01 and ***P < 0.001 compared with corresponding non-diabetic control group; ### P < 0.001 compared with saline/vehicle 2-week diabetic group. ++ P < 0.01 compared saline/Glb (1 mg/kg) 2-week diabetic group. protective event against epileptic activity via attenuating the danger of over-stimulation of glutamate transmission at CA3 synapses. 53 Pharmacological studies have demonstrated that K ATP channels play an important role in the control of seizure threshold in several in vitro and in vivo models. 3, [7] [8] [9] [10] [11] [12] 54 Moreover, it has been shown that mice lacking a subunit of K ATP channels (Kir 6.2 À/À mice) are vulnerable to hypoxia, exhibiting a reduced threshold for generalized seizure. 9 Transgenic mice, overexpressing the SUR1 gene in the forebrain, show a significant increase in the threshold for kainate-induced seizures. 13 Consistently, we have recently reported that K ATP channel openers such as cromakalim and diazoxide increased the clonic seizures induced by PTZ in mice. 7, 8 The PTZ-induced clonic seizures primarily model a type of forebrain-regulated seizures that are associated with increased activity in major epileptogenic centers of forebrain like amygdala and piriform cortex. [55] [56] [57] In the present study, we showed that in diabetic mice the PTZinduced seizure threshold was altered in a time-dependent manner, reaching a peak on week 2 after STZ injection and declining afterwards. Although these data suggest that the period of experimental diabetes seems to play an important role in the observed effects of diabetes on the PTZ-induced seizure threshold, previous studies have shown that the seizure susceptibility is increased in diabetic animals. [29] [30] [31] [32] This differences in results could be explained by the fact that in the present study we used the PTZ model of seizure threshold in mice which is different with the previous studies. We interestingly demonstrated that a noneffective dose of the specific K ATP channel blocker could inhibit the increased seizure threshold induced by PTZ in 2-week diabetic mice and a non-effective dose of the selective K ATP channel opener cromakalim increased the seizure threshold in 8-week diabetic mice, suggesting that K ATP channels may play an essential role in the time-dependent alterations in the seizure threshold in diabetic mice. In agreement with this assumption, several line of evidence have indicated that the alterations in the K ATP channel functioning in diabetic condition is dependent on the duration of the disease. For instance, Kersten et al. have found that the dilation of small coronary arteries induced by the K ATP channel opener was increased in alloxan-induced 1-week diabetic dogs. 40 Ikenaga et al. also reported that only 2 weeks after STZ injection, rat isolated renal afferent arterioles exhibited exaggerated responses to the K ATP channels openers pinacidil and PCO-400. 43 They suggested that the functional availability of afferent arteriolar K ATP channels may be increased during the early stage of diabetes, or that the impact of these channels on membrane potential is exaggerated. 43 In our recent study, a significant enhancement in the cromakaliminduced relaxation of isolated corpus cavernosum was observed in 2-week diabetic rats, whereas the relaxant responses to cromakalim were decreased in 6-and 8-week diabetic rats. 44 According to these reports and considering the anticonvulsant property of K ATP channel activation, it could be suggested that the enhanced seizure threshold in 2-week diabetic mice in the present study could be due to the enhanced activity of central K ATP channels, since a non-effective dose of glibenclamide could prevent this enhancement. An increased K ATP channel activity at this time may be associated with a very high metabolic state (i.e. low ATP levels) of cells relatively soon after the initiation of hyperglycemia. This is in line with the fact that K ATP channels are gated by intracellular ATP/ADP concentrations 6,58 coupling cell metabolic events to electrical activity. 59 However, this general assumption has to await more detailed studies evaluating the activity of K ATP channels in brain regions especially forebrain that is associated with the seizures induced by PTZ. Our data also revealed that compared to the 2-week diabetic animals seizure threshold was significantly decreased in 4-, 6-and 8-week diabetic animals. The seizure threshold was even lower that control levels in 8-week diabetic mice, though it was not significant. The deterioration in the seizure threshold could be discussed by the profound effects of diabetic condition on the central nervous system. Accordingly, several studies have shown that in the adult diabetic patients hyperglycemia can precipitate seizures. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Animal studies also demonstrated that alloxaninduced diabetic hyperglycemia was associated with proconvulsant effects in the electroshock seizure model in the adult rats 29 and mice. 30 These observations could be explained by the adverse effects of long-term hyperglycemia on the seizure threshold in diabetic patients. 27, 31 We interestingly observed that the non-effective dose of cromakalim increased the seizure threshold in 8-week diabetic mice and this effect was blocked by glibenclamide. This might reflect a gradual deterioration of the function of K ATP channels during progression of diabetes. In agreement with this assumption, there is convincing evidence that relaxant responses to the K ATP channel openers are decreased in a variety of tissues from long-term diabetic animals including rat corpus cavernosum, 44 thoracic aorta, 60 basilar arteries 39 and cerebral arteries. 35, 36 Some studies also reported that chronic hyperglycemia induced a reduction in K ATP channel gene expression in the pancreas. [61] [62] [63] By linking neuronal metabolism and excitability K ATP play an important role in protecting cells from neuronal death caused by hypoxia, ischemia or metabolic inhibition. Increased K ATP channel activity in blood vessels during metabolic stress, such as during ischemia, could have a helpful effect on the maintenance of tissue perfusion. In this regard, Yamada et al. even reported that K ATP channels have protective role in the hypoxia-induced generalized seizure. 9 Therefore, it is reasonable to suggest that tissues could more susceptible to ischemic damage after extended periods of diabetes owing to impaired function of K ATP channels. Consistently, 64 have shown that both hypoxia-induced and aprikalim (a K ATP channel opener)-induced vasodilation of coronary arterioles were impaired in patients with both Type I and Type II diabetes. They also showed that K ATP channel blockade by glibenclamide reduced hypoxic vasodilation, suggesting that K ATP channels are involved in transducing vascular signals to reduced tissue oxygen concentrations in the human heart. Since impairment in the function of vascular system is one of the complications of long-standing diabetes, this even could affect the function of central nervous system and increase the seizure susceptibility via disturbing K ATP channels functioning. Taken our results together with previous studies, it could be suggested that the decrease in the PTZ-induced seizure threshold in chronic diabetic mice might be due to either decrease in the activity or expression of K ATP channels in the brain regions modulating the seizure susceptibility. However, more studies are clearly needed to verify this assumption.
In conclusion, in the present study we demonstrated a timedependent alteration in the seizure threshold in diabetic mice, reaching a peak on week 2 after STZ injection and declining afterwards. We also indicated that the alteration in the K ATP channel functioning during the diabetic state could be involved in this manner.
